Show simple item record

dc.contributor.authorBacken, Alison C
dc.contributor.authorRenehan, Andrew G
dc.contributor.authorClamp, Andrew R
dc.contributor.authorBerzuini, C
dc.contributor.authorZhou, C
dc.contributor.authorOza, A
dc.contributor.authorBannoo, S
dc.contributor.authorScherer, S
dc.contributor.authorBanks, R
dc.contributor.authorDive, Caroline
dc.contributor.authorJayson, Gordon C
dc.date.accessioned2014-07-08T13:56:52Z
dc.date.available2014-07-08T13:56:52Z
dc.date.issued2014-06-19
dc.identifier.citationThe combination of circulating Ang1 and Tie2 levels predict progression free survival advantage in Bevacizumab-treated ovarian cancer patients. 2014: Clin. Cancer Res.en
dc.identifier.issn1078-0432
dc.identifier.pmid24947924
dc.identifier.doi10.1158/1078-0432.CCR-13-3248
dc.identifier.urihttp://hdl.handle.net/10541/322559
dc.description.abstractPurpose: Randomized ovarian cancer trials, including ICON7, have reported improved progression-free survival (PFS) when bevacizumab was added to conventional cytotoxic therapy. The improvement was modest prompting the search for predictive biomarkers for bevacizumab. Experimental Design: Pre-treatment training (n = 91) and validation (n = 114) blood samples were provided by ICON7 patients. Plasma concentrations of 15 angio-associated factors were determined using validated multiplex ELISAs. Results: The combined values of circulating Ang1 and Tie2 concentrations predicted improved PFS in bevacizumab-treated patients in the training set. Using median concentrations as cut-offs, high Ang1/low Tie2 values were associated with significantly improved PFS for bevacizumab-treated patients (median: 23.0 months versus 16.2, log rank test, p=0.006). High Ang1/high Tie2 values were associated with a poor outcome for bevacizumab-treated patients (median: 12.8 months versus 28.5 months, log rank test p=0.007). Ang1 and Tie2 jointly interacted with the effect of bevacizumab on PFS (pinteraction=0.003). The prognostic indices derived from the training set differentiated classes of high and low probability for progression in the validation set (p = 0.008). Conclusions: The combined values of Ang1 and Tie2 are predictive biomarkers for improved PFS in bevacizumab-treated patients with ovarian cancer.
dc.languageENG
dc.language.isoenen
dc.rightsArchived with thanks to Clinical cancer research : an official journal of the American Association for Cancer Researchen
dc.titleThe combination of circulating Ang1 and Tie2 levels predict progression free survival advantage in Bevacizumab-treated ovarian cancer patients.en
dc.typeArticleen
dc.contributor.departmentClinical Experimental Pharmacology, Cancer Research UK Manchester Institute.en
dc.identifier.journalClinical Cancer Researchen
refterms.dateFOA2020-05-01T14:07:51Z
html.description.abstractPurpose: Randomized ovarian cancer trials, including ICON7, have reported improved progression-free survival (PFS) when bevacizumab was added to conventional cytotoxic therapy. The improvement was modest prompting the search for predictive biomarkers for bevacizumab. Experimental Design: Pre-treatment training (n = 91) and validation (n = 114) blood samples were provided by ICON7 patients. Plasma concentrations of 15 angio-associated factors were determined using validated multiplex ELISAs. Results: The combined values of circulating Ang1 and Tie2 concentrations predicted improved PFS in bevacizumab-treated patients in the training set. Using median concentrations as cut-offs, high Ang1/low Tie2 values were associated with significantly improved PFS for bevacizumab-treated patients (median: 23.0 months versus 16.2, log rank test, p=0.006). High Ang1/high Tie2 values were associated with a poor outcome for bevacizumab-treated patients (median: 12.8 months versus 28.5 months, log rank test p=0.007). Ang1 and Tie2 jointly interacted with the effect of bevacizumab on PFS (pinteraction=0.003). The prognostic indices derived from the training set differentiated classes of high and low probability for progression in the validation set (p = 0.008). Conclusions: The combined values of Ang1 and Tie2 are predictive biomarkers for improved PFS in bevacizumab-treated patients with ovarian cancer.


Files in this item

Thumbnail
Name:
4549.full.pdf
Size:
402.4Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record